You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

About Ovarian Cancer

Ovarian cancer is rare but deadly1

A Diagnosis of Advanced-Stage Ovarian Cancer Often Leads to Poor Prognosis2

Despite optimal surgical outcomes and high response rates to 1L platinum-based chemotherapy, the outlook in advanced ovarian cancer remains poor3,4

There is a need for a maintenance therapy that3,6-8

Need for maintenance therapy chart

PROLONGS

progression-free survival
Need for maintenance therapy chart

EXTENDS

PARP inhibitor therapy to more women9-11
Need for maintenance therapy chart
Offers

CONVENIENT

once-daily, oral dosing

1L, first-line; BRCA, breast cancer susceptibility gene; CI, confidence interval; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival.

1L, first-line; BRCA, breast cancer susceptibility gene; CI, confidence interval; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival.

Efficacy data

EFFICACY DATA

View efficacy data for all indications

See the Data

STUDY DESIGN

See the PRIMA clinical trial design

View Trial Info
Back to Top